CD274 and renal cell carcinoma: Another clinical trial assessed the outcomes of patients with late-stage RCC or NSCLC who received anti-PD-L1 monoclonal antibodies alone or in combination with antibiotics (quinolones or β-lactams) within 4 days of treatment initiation and observation that the addition of antibiotics reduced OS in NSCLC and PFS in those with RCC 291.